Ureteral stent versus no stent for adults having radical cystectomy with an ileal conduit

Randomized Controlled Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

Not applicable Interventional Thomas Jefferson University · NCT07234968

This trial tests whether placing temporary ureteral stents at the time of radical cystectomy with ileal conduit reduces post-operative complications compared with not placing stents in adults having cystectomy for bladder or other pelvic cancers.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment70 (estimated)
Ages18 Years to 85 Years
SexAll
SponsorThomas Jefferson University Academic / other
Drugs / interventionsradiation
Locations2 sites (Philadelphia, Pennsylvania and 1 other locations)
Trial IDNCT07234968 on ClinicalTrials.gov

What this trial studies

This is a prospective randomized trial assigning patients 1:1 to receive intraoperative ureteral stents or no stents during radical cystectomy with ileal conduit, with randomization stratified by surgical approach (open, robotic, or hybrid). Stents, when placed, are removed typically between 7 and 21 days post-operatively at the surgeon's discretion. Participants follow standard clinical care and are seen at 30 days, 3 months, 6 months, and 12 months after surgery, with additional visits if stent replacement or interventions are needed. The study will compare rates of post-operative complications such as urinary leak, urinary tract infection, need for re-intervention, and related morbidity over a 12-month follow-up period.

Who should consider this trial

Good fit: Adults aged 18–85 who are scheduled for radical cystectomy with ileal conduit for bladder or other pelvic malignancies, can consent and attend follow-up, and do not have recent pelvic radiation or an untreated UTI are ideal candidates.

Not a fit: Patients with prior pelvic radiation, retroperitoneal fibrosis, untreated urinary tract infection, pregnancy, or those receiving other types of urinary diversion are unlikely to benefit or be eligible for this protocol.

Why it matters

Potential benefit: If successful, the approach could reduce urinary leaks, infections, and reoperations after cystectomy and improve post-operative recovery.

How similar studies have performed: Existing observational and institutional reports show mixed results on routine stent use and randomized evidence is limited, so this trial addresses an evidence gap.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Individuals must meet all the following inclusion criteria to be eligible to participate in the study:

  * Provide signed and dated informed consent form
  * Willing to comply with all study procedures and be available for the duration of the study
  * Male or female, age 18 to 85
  * Diagnosed with bladder cancer, other pelvic malignancies necessitating a cystectomy (e.g.: colorectal, prostate, gynecologic) and have elected for a cystectomy with ileal conduit urinary diversion

Exclusion Criteria:

* An individual who meets any of the following criteria will be excluded from participation in this study:

  * Current or history of pelvic radiation
  * Retroperitoneal fibrosis
  * Untreated urinary tract infection (UTI) within 30 days prior to RCIC
  * Pregnancy

Where this trial is running

Philadelphia, Pennsylvania and 1 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Bladder CancerMuscle-Invasive Bladder CarcinomaUrothelial CarcinomaPelvic MalignancyBladder Transitional Cell CarcinomaBladder NeoplasmBladderStent-free Cystectomy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.